
pmid: 24010909
This article presents an overview of positron emission tomography combined with computed tomography (PET/CT) imaging of bone tumors for the practicing radiologist. The clinical roles and utility of (18)F-labeled fluorodeoxyglucose PET/CT in patients with primary bone tumors, osseous metastases, and multiple myeloma are reviewed. The clinical and research data supporting the utility of PET/CT in the evaluation of skeletal malignancies continues to grow.
Biopsy, Contrast Media, Bone Neoplasms, Multimodal Imaging, Sensitivity and Specificity, Fluorodeoxyglucose F18, Lymphatic Metastasis, Humans, Radiopharmaceuticals, Multiple Myeloma, Radionuclide Imaging, Neoplasm Staging
Biopsy, Contrast Media, Bone Neoplasms, Multimodal Imaging, Sensitivity and Specificity, Fluorodeoxyglucose F18, Lymphatic Metastasis, Humans, Radiopharmaceuticals, Multiple Myeloma, Radionuclide Imaging, Neoplasm Staging
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 20 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
